ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR123

B Cell Deficiency Inhibits Chronic Antibody Mediated Rejection in a Th1 and IL-10 Dependent Pathway in a Rat Kidney Transplant Model

Session Information

Category: Transplantation

  • 1701 Transplantation: Basic and Experimental

Authors

  • Panzer, Sarah E., University of Wisconsin Madison, Madison, Wisconsin, United States
  • Reese, Shannon, University of Wisconsin Madison, Madison, Wisconsin, United States
  • Wilson, Nancy A., University of Wisconsin Madison, Madison, Wisconsin, United States
  • Ptak, Lucille D, University of Wisconsin Madison, Madison, Wisconsin, United States
  • Renteria, Isabelle S, University of Wisconsin Madison, Madison, Wisconsin, United States
  • Djamali, Arjang, University of Wisconsin Madison, Madison, Wisconsin, United States
Background

The pathologic role of B cells in chronic antibody mediated rejection (cAMR) remains unclear.

Methods

We generated B cell deficient Lewis rats (B-/-) via CRISPR technology. Kidney transplantation was performed in 4 groups: syngeneic (Lewis to Lewis), allogeneic (Fisher to Lewis), sensitized (Fisher to Lewis 3 weeks following donor-specific blood transfusion), and allogeneic B cell deficient recipients (Fisher to B-/- Lewis). All animals were harvested at 6 months.

Results

cAMR was reduced in B-/- recipients compared to allogeneic and sensitized recipients based on Banff scores for microvascular inflammation (allogeneic: 3.0±1.7, sensitized: 4.6±0.5, B-/-: 1.5±0.6; P=0.001) and C4d staining (allogeneic: 1.5±0.6, sensitized: 2.2±0.8, B-/-: 0.5±0.6; P=0.05). Allograft deposition of IgM was significantly reduced in B-/- compared to allogeneic recipients (Fig1A). Intragraft macrophages and fibrosis by Picrosirius red stain demonstrated no differences among allogeneic, sensitized, and B-/- recipients (Fig1B). Th1 (IL-2 and IFN-gamma) and IL-10 cytokines by RT PCR were significantly reduced in B-/- compared to allogeneic recipients, but not Th2 (IL-4 and IL-6) or Th17 (Fig1C). Chronicity scores (Banff chronicity score = cg + ct + ci + cv) were elevated in allogeneic, sensitized, and B-/- recipients (3.0±1.7, 4.6±0.5, and 1.5±0.6, respectively).

Conclusion

B cell deficiency inhibits cAMR in a Th1 and IL-10 dependent pathway. Further studies are needed to determine the contributions from non-B cell mediated factors, such as innate immunity, to the development of fibrosis in chronic rejection.

Figure 1. B cell deficient recipients demonstrated reduced allograft inflammation. (A) Immunoflourescence showed absent antibody deposition in the allografts of B-/- recipients. (B) Fibrosis, as determined by Picorsirius red stain, was unchanged among allogeneic, sensitized, and B-/- recipients. (C) RT PCR of allografts demonstrated a reduction in Th1 cytokines (IL-2, IFN-gamma) and IL-10.

Funding

  • Other NIH Support